Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xeomin for Troublesome Sialorrhea in PD and ALS
NCT01565395Phase 2Withdrawn
- Sponsor
- Beth Israel Deaconess Medical Center
- Start
- Mar 2012
- Primary completion
- Jul 2013
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in sialorrhea comparing Xeomin First with Placebo First (2 arms). Primary endpoint: Change in objectively measured salivary volume at 1 month. Planned start Mar 2012; status: withdrawn.
02
Drugs
botulinum toxin type A
03
Conditions
sialorrhea
Beyond the preview
Go deeper on NCT01565395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01565395.